Neuspera Gains Medicare Reimbursement Parity for Sacral Neuromodulation

Under the proposed CY 2027 Outpatient Prospective Payment System, the Neuspera system is assigned to APC 5464, which also sees its payment rate climb to $22,150—an 11.8% increase over previous levels. This regulatory alignment places Neuspera on equal footing with established manufacturers like Medtronic and Boston Scientific, effectively removing a financial barrier that previously favored systems relying on large, implanted batteries.

Traditional sacral neuromodulation devices have long required surgical creation of a pocket to house bulky batteries, often leading to complications such as site pain, infections, and the need for multiple battery replacements over a patient’s lifetime. A recent Cleveland Clinic study highlighted these burdens, noting that 62% of patients report feeling their device, while 36% experience discomfort during daily activities. By eliminating the internal battery, the Neuspera system aims to mitigate these risks and attract a broader patient demographic that has previously avoided surgery due to concerns over device size and maintenance.

Neuspera CEO David Van Meter described the CMS decision as a victory for patient choice, noting that the company’s technology now benefits from the same National Coverage Determination 230.18 as legacy therapies. As the company continues to enroll participants in its FREEDOM registry, clinicians such as Dr. Charles R. Powell of Indiana University suggest that the ability to offer a smaller, externally powered alternative may soon establish this approach as the preferred standard for patients seeking relief from urinary urge incontinence.